Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Refractory Chronic Cough


About this study

Study of the efficacy, safety, and tolerability of serlopitant for the treatment of refractory chronic cough.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Female and males between 18 and 80 years of age
  • Have a diagnosis of treatment refractory chronic cough or unexplained cough for at least one year
  • Chest radiograph or computed tomography (CT) Thorax within the last 5 years not demonstrating any abnormality considered to be significantly contributing to the chronic cough
  • At Screening have a score of ≥ 40mm on the Cough Severity VAS
  • At Baseline (Day 0) have a score of ≥ 40mm on the Cough Severity VAS
  • All female subjects who are of childbearing potential must practice highly effective contraception (i.e., pregnancy prevention method with a failure rate of < 1% per year) from the time of the initial screening visit until 4 weeks after last dose of study drug. Please refer to the protocol for acceptable methods of contraception

Exclusion Criteria:

  • Prior treatment with serlopitant or other NK1-R antagonist
  • Presence of any medical condition or disability that could interfere with study
  • History of hypersensitivity to serlopitant or any of its components
  • Currently pregnant or male partner of pregnant female
  • Females of childbearing potential who are unable or unwilling to use adequate contraception or who are breast feeding
  • Current smoker or individuals who have given up smoking within the past 12 months
  • FEV1/FVC < 60%
  • Body mass index (BMI) <18 kg/m2 or ≥ 40 kg/m2 at Screening
  • History of upper or lower respiratory tract infection or recent significant change in pulmonary status within 4 weeks of the Baseline Visit (Day 0)
  • History of cystic fibrosis
  • History of opioid use within 1 week of the Baseline Visit (Day 0)
  • Requiring concomitant therapy with prohibited medications
  • Treatment with biologic therapies within 8 weeks or 5 half-lives prior to the Baseline Visit (Day 0), whichever is longer
  • Treatment with strong CYP3A4 inhibitors within 4 weeks prior to the Baseline Visit (Day 0)
  • Treatment with any investigational therapy within 4 weeks (investigational biologic therapies within 8 weeks) prior to the Baseline Visit (Day 0)
  • Serum creatinine, total bilirubin, alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2x the upper limit of normal (ULN) during screening
  • Positive test for any drug of abuse
  • History of malignancy within 5 years prior to the Baseline Visit (Day 0), with the exception of completely treated and non-metastatic basal cell carcinoma or squamous cell carcinoma of the skin
  • Any known psychiatric diagnosis meeting DSM-5 criteria which may confound the assessment of serlopitant safety or efficacy, or interfere with the subject's ability to comply with protocol-mandated activities, within 3 years prior to randomization. Examples of such DSM-5 diagnoses include but are not limited to major depressive disorder, bipolar disorder, schizophrenia, psychotic disorder, intellectual disability, severe alcohol use disorder.
  • Known active hepatitis infection
  • Known history of human immunodeficiency virus (HIV) infection

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Vivek Iyer, M.D., M.P.H.

Closed for enrollment

More information


Publications are currently not available

Mayo Clinic Footer